Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Payal Deepak Shah, Shanu Modi, Farrah Mikhail Datko, Mary Ellen Moynahan, Stephen Zamora, Gabriella D'Andrea, Diana Lake, Shari Beth Goldfarb, Sujata Patil, Sharat Singh, Emma J. Langley, Phillip Sangwook Kim, Anne M. Covey, Betty Ann Caravella, Michael F. Berger, Mario E. Lacouture, Clifford A. Hudis, Jose Baselga, Sarat Chandarlapaty, Maura N. Dickler
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2604085198